Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Summary Background The randomised phase 3 TURANDOT trial compared two approved bevacizumab-containing regimens for HER2-negative metastatic breast cancer in terms of efficacy, safety, and quality of life. The interim analysis did not confirm non-inferior overall survival (stratified hazard ratio [HR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The lancet oncology 2016-09, Vol.17 (9), p.1230-1239
Hauptverfasser:	Zielinski, Christoph, Prof, Láng, István, Prof, Inbar, Moshe, Prof, Kahán, Zsuzsanna, Prof, Greil, Richard, Prof, Beslija, Semir, Prof, Stemmer, Salomon M, MD, Zvirbule, Zanete, MD, Steger, Günther G, MD, Melichar, Bohuslav, Prof, Pienkowski, Tadeusz, MD, Sirbu, Daniela, MD, Petruzelka, Luboš, Prof, Eniu, Alexandru, MD, Nisenbaum, Bella, MD, Dank, Magdalena, Prof, Anghel, Rodica, Prof, Messinger, Diethelm, MSc, Brodowicz, Thomas, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Biomarkers Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer therapies Capecitabine - administration & dosage Chemotherapy ErbB-2 protein Estrogens Feet Female Follow-Up Studies Health risk assessment Hematology, Oncology and Palliative Medicine Humans Immunotherapy Leukopenia Medical prognosis Metastases Metastasis Monoclonal antibodies Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - metabolism Neoplasm Recurrence, Local - pathology Neoplasm Staging Neutropenia Oncology Paclitaxel Paclitaxel - administration & dosage Patients Peripheral neuropathy Progesterone Prognosis Quality of Life Receptor, ErbB-2 - metabolism Risk factors Survival Survival Rate Targeted cancer therapy Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!